GF Fund Management’s Sage Therapeutics SAGE Stock Holding History

GF Fund Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,566	Closed	-$14.3K	–	672
2025 Q2	$14.3K	Hold	1,566	–	–	﹤0.01%	531
2025 Q1	$12.4K	Buy	1,566 +282	+22%	+$2.06K	﹤0.01%	534
2024 Q4	$6.97K	Buy	+1,284	New	+$7.85K	﹤0.01%	588

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GF Fund Management's SAGE Position: Q3 2025 in Review

GF Fund Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,566 shares — an estimated $14.3K sold.

GF Fund Management first reported a position in SAGE in Q4 2024 and held it in 3 quarters. The position peaked at $14.3K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

GF Fund Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
GF Fund Management sold 1,566 Sage Therapeutics shares in Q3 2025, an estimated $14.3K.
GF Fund Management first reported a position in Sage Therapeutics in Q4 2024 and held it in 3 quarters.
GF Fund Management's Sage Therapeutics position peaked at $14.3K in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.